Viruses vs. superbugs: new hope for skin infections?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * (1) Aged 18 to 75 years, regardless of gender. (2) Clinically diagnosed with a skin infection, with an infected wound area of 4-225 cm². (3) The infection does not involve deep tissues, is suitable for topical treatment, and is not expected to require surgical intervention. (4) Pathogenic bacteria are detected in secretions or wound samples. (5) The pathogen is resistant to key antibiotics (such as carbapenems, etc.), or, despite being susceptible in vitro, shows poor response to antibiotic therapy. (6) Patients who have received systemic antibacterial therapy within 72 hours prior to enrollment without significant improvement may also be included. (7) Subjects of childbearing potential must agree to use effective contraception during the study period. (8) Voluntarily sign the informed consent form, and are willing and able to comply with the requirements of the study protocol. Exclusion Criteria: * (1) The infection can be effectively controlled by available antimicrobial agents, or the causative pathogen is insensitive to the phage cocktail used in this study. (2) Pregnant or breastfeeding women. (3) Patients who have used antimicrobial agents within 72 hours prior to enrollment and have shown improvement in infection symptoms. (4) Patients currently receiving prolonged or high-dose corticosteroids, immunosuppressants, chemotherapy, or other treatments that may interfere with the study results. (5) Patients who have participated in other clinical trials related to antimicrobial agents within the past month. (6) Patients with severe wound infections (e.g., necrotizing fasciitis), chronic inflammatory skin diseases, multiple limb ulcers, non-removable implants, or gangrene, among other conditions. (7) Patients expected to require amputation surgery. (8) Patients with a documented history of allergic disorders, immunodeficiency (including HIV positivity), mental disorders, or epilepsy. (9) Any other condition deemed by the investigator as unsuitable for participation in this study.